BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind ...
(RTTNews) - Labcorp (LH) announced the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma ...
Labcorp's Menopause Test and Menopause Support Program provide women with insights to guide their healthcare decisions BURLINGTON, N.C., July 24, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global ...
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
BURLINGTON, North Carolina -- LabCorp has received emergency use authorization from the Food and Drug Administration for its Pixel at home coronavirus test kit. The COVID-19 At Home Test Kit allows ...
Partnership will distribute screening kits to communities at higher risk of colon cancer BURLINGTON, N.C., April 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, is ...
The new test measures the risk of preeclampsia with up to 90% sensitivity and 90% specificity, according to Labcorp. Photo by Adobe Stock/HealthDay News Preeclampsia can be a life-threatening ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback